SynthesisBMC cardiovascular disorders2025
Effect of percutaneous coronary intervention on chronic total occlusions with documented viability or ischemia: a systematic review and meta-analysis.
Synthesis in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPercutaneous coronary intervention (PCI) for chronic total occlusions (CTO) is common despite the equivocal evidence regarding its benefits. This study aimed to evaluate the impact of pre-PCI viability or ischemia assessment on left ventricular (LV) function, ischemic burden, symptoms, and major adverse cardiovascular events in CTO patients.
methodsA systematic search of PubMed/MEDLINE, EMBASE, CENTRAL, Web of Science Core Collection, ClinicalTrials.eu, and ClinicalTrials.gov was conducted. Studies assessing viability and/or ischemia before PCI with follow-up data were included. Quality was assessed using Cochrane Risk of Bias 2.0 and ROBINS-I tools. Meta-analyses were conducted for quantitative outcomes and narrative synthesis for heterogeneous data. A total of 21 studies (3 randomized, 18 observational) were included; notably, among the randomized trials, only one required the presence of viability or ischemia as an inclusion criterion.
resultsTwenty-one studies were included in this review. Cardiac magnetic resonance was the most used imaging modality, followed by positron emission tomography. Successful PCI was associated with improved LV ejection fraction (MD: 3.97%; 95% CI: 1.51% to 6.42%) but no significant change in LV volumes. Regional segmental wall thickness increased in dysfunctional viable segments (MD: 16.70%; 95% CI: 11.15% to 22.26%), but not in non-viable segments. Successful CTO-PCI improved hyperaemic myocardial blood flow (MBF) (MD: 1.03 mL/min/g; 95% CI: 0.94 mL/min/g to 1.13 mL/min/g), rest MBF (MD: 0.10 mL/min/g; 95% CI: 0.06 mL/min/g to 0.14 mL/min/g), and coronary flow reserve (MD: 1.16; 95% CI: 1.03 to 1.30). The extent of ischemia reduction was associated with improved long-term prognosis and symptom relief.
conclusionsPre-PCI viability and ischemia assessment may help identify patients more likely to achieve better functional recovery and symptom relief after successful CTO recanalization. These findings support its role in patient selection and highlight the need for further randomized studies to confirm prognostic value.
trial registrationThe review protocol was registered in PROSPERO (ID: CRD42023426858).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.